Fig. 5
Efficacy of 4 ACT-101-maytansinoid conjugates in the COLO-205 xenograft model. A Inhibition of tumor growth. Changes in mean tumor weight following implantation (tumor weight is estimated as V = (L xW2)/2 where V is volume (with density assumed to be close to 1 g/mL and Weight = V), L is tumor length, and W is tumor width; The bars represent standard deviation, n = 10 per group. Statistical significance was determined by Kruskal Wallace & Dunnett’s on Ranks, followed by Wilcoxon test. Tumor growth was significantly slower (p < 0.05) in all groups compared to vehicle control. B Survival. Calculated as % of animals alive on a given day compared to total number of animals in the group. All surviving animals were euthanized at day 60 post implantation. Group 1: ACT-101-ABZ982 (DPR 3.74) 20 mg/kg, Group 2: ACT-101-ABZ982 (DPR 5.81) 10 mg/kg, Group 3: ACT-101-ABZ1827 (DPR 3.92) 10 mg/kg, Group 4: ACT-101-ABZ1827 (DPR 5.96) 20 mg/kg, Group 5: Vehicle control